drugset / Trial / NCT02621177

Study of Egg-derived Influenza Vaccine and Cell Culture-derived Influenza Vaccine in Healthy Children and Adolescents

NCT02621177

Phase 3 Completed 385 enrolled SK Chemicals Co., Ltd.
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This study is a multi-center, randomized, double-blind Phase III clinical trial. The aim of the study is to describe the immunogenicity and safety of the trivalent cell culture-derived influenza vaccine compared to the trivalent egg-derived influenza vaccine among subjects.

Timeline

Start
2013-11
Primary completion
2014-03
Completion
2014-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Agrippal S1 Vaccine 0.25 ml Intramuscular
Comparator Agrippal S1 Vaccine 0.5 ml Intramuscular
Subject NBP607 Vaccine 0.25 ml Intramuscular
Subject NBP607 Vaccine 0.5 ml Intramuscular

Indications